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Summary Non-invasive predictive assays which can confirm the presence or absence of hypoxic cells in
human tumours show promise for understanding the natural history of tumour oxygenation, and improving
the selection of patient subsets for novel radiotherapeutic strategies. Sensitiser adducts have been proposed as
markers for hypoxic cells. Misonidazole analogues radiolabelled with iodine-123 have been developed for the
detection of tumour hypoxia using conventional nuclear medicine techniques. In this pilot study, we have
investigated one such potential marker,'23I-iodoazomycin arabinoside ('231-IAZA). Patients with advanced
malighancies have undergone planar and single-photon emission computed tomographic (SPECT) imaging
after intravenous administration of '23I-IAZA. We have observed radiotracer avidity in three out of ten
tumours studied to date. Normal tissue activity of variable extent was also seen in the thyroid and salivary
glands, upper aerodigestive tract, liver, intestine, and urinary bladder. Quantitative analysis of those images
showing radiotracer avidity revealed tumour/normal tissue (T/N) ratios of 2.3 (primary small cell lung
carcinoma), 1.9 (primary malignant fibrous histiocytoma) and 3.2 (brain metastasis from small cell lung
carcinoma) at 18-24 h post injection. These preliminary data suggest that the use of gamma-emitter labelled
2-nitroimidazoles as diagnostic radiopharmaceuticals is feasible and safe, and that metabolic binding of
'23I-IAZA is observed in some, but not all tumours. The inference that tumour 1231-IAZA avidity could be a
non-invasive measure of tumour hypoxia deserves independent confirmation with needle oximetry.
Indirect evidence from clinical observations has suggested
that chronic cellular hypoxia influences the radiocurability of
some human malignancies (Bush et al., 1978; Henk & Smith,
1977; Urtasun et al., 1976). Trials of strategies to overcome
the oxygen effect have had no reliable technique available for
confirming the presence of hypoxic cells in tumours of the
patients on study. For this reason, the development of
predictive assays of tumour oxygenation status is of great
interest in radiotherapy. In a study of oxygen tension mapp-
ing in cervical lymph node metastases from squamous cell
carcinomas of the head and neck, Gatenby et al. (1985, 1988)
showed that extensive areas of hypoxia, determined by
oxygen electrode measurements, were significantly correlated
with tumour radioresponse, and were independent of tumour
bulk. Radiosensitiser adduct formation has been shown to
identify hypoxic cells in vitro and in solid animal tumour
models (Chapman et al., 1981; Garrecht & Chapman, 1983;
Franko et al., 1982). Clinical data from a study of 3H-
misonidazole in advanced cancer patients show evidence for
hypoxic regions in biopsies of subcutaneous metastases. In
this study, hypoxic fractions of potential clinical significance
were determined to be present in 3/3 melanomas, 8/12 small
cell lung carcinomas, 1/10 soft tissue sarcomas, and 0/2
squamous cell carcinomas of the head and neck (Chapman et
al., 1989a). This technique, however, is invasive, requires
careful radiation protection safeguards, is only applicable to
accessible lesions and is time consuming. Therefore, rapid,
non-invasive predictive assays for hypoxia are under develop-
ment.
The radioiodinated azomycin nucleosides are misonidazole
analogues labelled with iodine-123 which show promise for
use in the detection of tumour hypoxia using conventional
nuclear medicine techniques (Jette et al., 1986; Wiebe et al.,
1986). Iodoazomycin arabinoside (Figure 1, IAZA) has been
shown to undergo hypoxia-dependent binding and is
cytotoxic to EMT-6 tumour cells in vitro (Mannan et al.,
1991; Mercer et al., 1990). Recently, it has been shown using
autoradiography that '25I-IAZA binds to hypoxic regions of
EMT-6 spheroids in a manner analogous to 3H-misonidazole
(G.G. Miller, Ph.D., personal communication). Whole body
biodistribution studies using implanted EMT-6 tumours in
BALB/c mice show a maximum tumour to whole blood ratio
of 8.7 at 8 h post injection. These promising results have lead
to the current clinical study investigating '23I-iodoazomycin
arabinoside ('23I-IAZA) as a potential non-invasive marker
for hypoxia. The aim of this study is to establish the toxicity
of IAZA in patients, as well as its pharmacokinetics, bio-
distribution and tumour uptake. This work in progress forms
the basis for this report.
Materials and methods
Radiopharmaceuticals
Unlabelled IAZA (1-(5'-iodo-5'-deoxy-p-D-arabinofuranosyl)-
2-nitroimidazole), was prepared in the laboratories of one of
us (L.I.W.) as described elsewhere (Mannan et al., 1991). In a
typical synthesis 1,110 MBq (30 mCi) of 1231 as NaI (Nordion
International Ltd., Vancouver, Canada), as a solution in
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Figure 1 lodoazomycin arabinoside.
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0.1 ml of 0.1 M NaOH contained in a 3 ml V-vial, was
evaporated to dryness at 40°C with a stream of nitrogen gas.
The dry residue was treated with 1.3 mg of IAZA and 3.1 mg
of pivalic acid as a solution in 100 tlI of methanol. A further
100 lI of methanol was used to wash down the walls and
concentrate the contents in the tip of the vial. This reaction
mixture was carefully dried with a stream of nitrogen gas at
40°C, sealed and heated at 75°C for 1.25 h. The cooled
sample was dissolved in 100 glI of aqueous methanol and
analysed by high pressure liquid chromatography (HPLC).
The chemical purity of the crude product was 96% with a 4%
impurity identified as 1-(,B-D-arabinofuranosyl)-2-nitroimi-
dazole, the hydrolysis product of IAZA. The radiochemical
purity was measured as 92.6% with a 4% impurity identified
as '231-iodide. The sample was purified by HPLC and the
solvent removed in vacuo. The patient dose was prepared by
dissolving the 231I-IAZA in 5.7 ml of sterile saline containing
10 mg of unlabelled IAZA and filtering the solution into a
sterile multidose vial. The purified sample had no detectable
chemical impurities and a >99% radiochemical purity when
analysed by HPLC. The mean activity was 223 MBq
(6.0 mCi); range, 145-343 MBq (3.9-9.3 mCi). The final
product (231I-IAZA) was dissolved in a total volume of 55 ml
sterile normal saline for injection.
Patient profile
To date, ten patients with advanced malignant solid tumours
of various histologies have been accrued to the trial. Appro-
priate written informed consent was obtained in all cases.
Inclusion criteria were: advanced solid tumours of the follow-
ing histologies: small cell lung cancer, malignant melanoma,
soft tissue sarcoma, high grade CNS glioma, and squamous
cell carcinoma of the head and neck; age less than or equal
to 75 years; Karnofsky performance status >,60%; satisfac-
tory hematological parameters (platelet count > 100 x 109 1',
WBC >3 x I091-, hemoglobin >100 g I-); hepatic and
renal function no more than 1.5 times normal range. Patient
characteristics are given in Table I.
Imaging protocol
231I-IAZA (mean, 223 MBq (6.0 mCi)) was given by slow
intravenous infusion over 20 min. Lugol's iodine was
administered orally for 3 days prior to imaging to block
thyroid uptake of free radioiodine. All imaging procedures
were performed using a General Electric 400 AC gamma
camera system. Image acquisition and processing was by
means of a Picker PCS 512 computer system. Anterior and
posterior planar static images were obtained of the area of
interest, thorax and abdomen typically at 1, 16, and 24 h
post injection. SPECT imaging of the area/region of interest
was performed between 16-24 h post infusion. It was found
that insufficient total body activity was retained for successful
imaging at times greater than 24 h. Consent was obtained
from three patients for blood sampling for the determination
of blood and plasma pharmacokinetics.
Qualitative assessment of biodistribution utilised both
planar and SPECT images. Quantitative analysis of the tissue
activity was assessed using region of interest analysis on these
images. On the planar images, using conjugate view counting
techniques (Thomas et al., 1988), tissue activity was deter-
mined using a square or rectangular region representing cen-
tral tumour activity. On the SPECT images, coronal, axial
and sagittal reconstructions were performed. For purposes of
activity quantification, tomographic slices were summed to
incorporate the entire dimensions of the tumour. Again,
tumour activity was represented by the central tumour
activity within a square or rectangular region of interest; an
identically sized region of interest in adjacent normal tissue
was then determined.
Results
Imaging results
Immediate and 1 h static images were obtained in all cases.
On early images we observed significant activity in the
thyroid gland, major salivary glands, paranasal sinuses,
nasal, oral, and pharyngeal mucosa, liver, kidneys and
urinary bladder. On later images, there was a relative in-
crease in thyroid and salivary gland activity, and loss of
hepatic and renal uptake; gastric, small, and large intestinal
activity became evident, as did activity in some tumours
(Figure 2). This suggested hepatic and renal routes of
elimination for 1231I-IAZA and/or its metabolites; also at least
partial in vivo deiodination was evident, accounting for
thyroid and salivary gland uptake.
Quantitative image analysis
Regions of interest were analysed sequentially to quantify
changes in relative tissue activity as a function of time
between the early and late images. This analysis showed focal
accumulation of activity in three of ten tumours. T/N ratios
were obtained by comparing a region of interest over the
tumour (T) and adjacent normal tissue (N). The T/N for
those tumours showing focal uptake increased with time, the
maximal T/N being 3.1 at 16h for a brain metastasis from
small cell lung carcinoma. The other tumours showing
uptake were a malignant fibrous histiocytoma of the thigh
(T/N = 1.9 at 22 h), and a primary small cell lung carcinoma
(T/N = 2.3 at 18 h) (Table II).
These data do not represent ratios of absolute quantities of
bound drug. Nonetheless, T/N ratios which increase over
time (comparing early and later images) can be taken as
evidence for preferential metabolic binding of the tracer in
tumours. We postulate that the rise in T/N shown by patients
1, 2 and 6 (+ 16%, + 16% and + 39% respectively, Table II)
represent this phenomenon, and that lesser changes or
decreases in T/N as exhibited by 7/10 patients probably do
not represent significant binding.
Table I Patient characteristics
Patient Age 1231-IAZA dose
number Sex (yrs) Diagnosis (MBq) Prior treatment
I M 75 Malignant fibrous histiocytoma ofthigh 180 3,500 cGy/15 fractions
2 F 58 Recurrent smallcell lungcarcinomawith brain 145 2,333 cGy/10 fractions
metastases
3 M 65 Glioblastomamultiforme 200 3,240cGy/18fractions
4 M 56 Limited stage smallcell lung carcinoma 145 Nil
5 F 59 Limited stage smallcell lungcarcinoma 260 Etanidazole 2.8 gi.v. x onedose
467 cGy/2 fractions
6 M 59 Limited stage small cell lungcarcinoma 288 Nil
7 M 70 Limited stage smallcelllungcarcinoma 306 OralVP-16 x onecycle
8 F 69 Limited stage smallcelllung carcinoma 187 IVCisplatinum/VP-16 x onecycle
9 F 47 Recurrent smallcell lungcarcinoma with brain 343 467 cGy/2 fractions
metastases
10 F 55 Glioblastomamultiforme 176 Nil92 M.B. PARLIAMENT et al.
Pharmacokinetics
Pharmacokinetic data were obtained in three cases. Aliquots
of whole blood were obtained from a peripheral vein via a 21
gauge cannula. Samples were taken every 2 min during the
infusion and thereafter every 15 min for the next hour and
then at appropriate intervals until 24 h. An early distribution
phase, followed by a slower clearance phase was identified
based on the biexponential form of the curves. Half-lives of
the distribution and clearance phases were calculated using
the method of residuals, assuming a two-compartment open
model. The average distribution half-life was 22.6 ± 8.7 min,
and the clearance half-life was 9.8 ± 4.1 h on average (Figure
3). These results are consistent with the previously reported
mean plasma half-life of 3H-misonidazole of 9 h (clearance
phase) (Urtasun et al., 1986; Chapman et al., 1989a). We
estimated on the basis of these data plus previous results
showing the half-life of sensitiser adducts in animal tumour
systems to be 50-55 h (Garrecht & Chapman, 1983; Chap-
man et al., 1983), that the optimum differential tissue activity
between bound drug vs background would occur at > 24 h
post 123I-IAZA infusion.
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Toxicity
Intravenous administration of '23I-IAZA resulted in acceptable
or no toxicity in all cases. The assessment was obtained by
patient interview. Specifically, one patient experienced tran-
sient somnolence upon commencement of the infusion, which
abated at the end of the infusion; one patient experienced
slight drowsiness during the infusion, however he had
received metoclopramide 10 mg i.v. immediately prior to the
infusion; and one patient noted a mild transient chill during
the infusion, without fever or diaphoresis. No cardiovascular,
gastrointestinal, or peripheral nerve toxicity was noted.
Discussion
There is evidence indicating that sensitiser adduct formation
offers a measure of intracellular oxygen concentration. It is
known that the radical anion generated by the initial one
electron reduction of 2-nitroimidazoles is oxidised in the
presence of sufficient oxygen (Rauth, 1984; Varghese & Whit-
more, 1984). In hypoxic cells, however, further reduction of
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Figure 2 a, SPECT image of brain (axial reconstruction) of a 58 year old woman with right frontal and right parietal metastases from small cell lung carcinoma, 18 h after infusion of 145 MBq of '231-IAZA. The right parietal lesion was '231-IAZA-avid with T/N = 3.2 (right parietal metastasis vs normal left parietal lobe). The right frontal lesion was not '231-IAZA-avid. Left and right are denoted (L), (R) respectively. b, SPECT image of thorax (anterior coronal reconstruction) of a 59 year old man with an untreated small cell lung carcinoma affecting the right upper hilum and mediastinum, 18 h after infusion of 288 MBq of '231I-IAZA. Significant activity was seen in the thyroid (Th), gut (G), liver (L), and tumour (T). c, SPECT image of thorax left sagittal reconstruction) of patient in Figure 2, b, showed '23I-IAZA avidity of the centrally located tumour (T). Thyroid (Th) displayed considerable artifact due to uptake of free 1231. (A) denotes anterior. d, SPECT images of thorax (axial reconstruction of patient in b. The right hilar/mediastinal tumour was '231-IAZA-avid with T/N = 2.3 (tumour vs chest wall). Left and right are denoted (L), (R) respectively.
Table II Results
Patient '231-IAZA TIN ratio Change in TIN between
number Diagnosis (at time) early and late images
1 MFH of thigh 1.9 (22 h)' + 16%
2 SCLC, brain mets 3.2 (18 h)b + 16%
3 Glioblastoma 1.3 (22 h)b + 2%
4 SCLC, limited stage 2.0 (18 h) + 9%
5 SCLC, limited stage 1.7 (18 h) + 2%
6 SCLC, limited stage 2.3 (18 h) + 39%
7 SCLC, limited stage 1.8 (24h)a - 10%
8 SCLC, limited stage 1.8 (20 h)a - 3%
9 SCLC, brain mets 1.0 (18 h)b - 8%
10 Glioblastoma 1.2 (17 h)b - 3%
aNormal tissue is skeletal muscle. bNormal tissue is normal brain. For abbreviations,
see text and Table I.
the radical anion can take place. The precise reactive
intermediate responsible for adduct formation with macro-
molecules is not known with certainty; the nitroso and hy-
droxylamine intermediates are possible candidates (Rauth,
1984; Varghese & Whitmore, 1984). The absolute rates of
binding to hypoxic cells are related to the concentration of
drug, the concentration of 02, and the duration of contact
between the drug and hypoxic tissues (Franko, 1986). To a
lesser extent, sensitiser binding rates are related to the struc-
ture of the particular 2-nitroimidazole (Chapman et al.,
1989c). It is also possible that constitutive levels of nitro-
reductase activity in various normal tissues affect the baseline
rates of binding (Cobb et al., 1990).
Besides efficient rates of binding to hypoxic tissues, there
are several other requirements for an ideal non-invasive
marker for hypoxia. Such a compound should have a parti-
tion coefficient which enables rapid diffusion into both well-
perfused and poorly-perfused tissues (Chapman et al.,
1989b). For successful imaging, a T/N which increases with
time is required. Therefore, relative differences in rates of
clearance of bound and unbound drug from tissues become
important in obtaining useful images. We have found that
three tumours showed a substantial rise in T/N between early
and later images, with increases of 16-39%. In those cases in
which the T/N did not increase with time, it is postulated
that tissue levels of unbound drug fell equally rapidly in
normal and tumour tissue, at a rate which simply reflected
the plasma level of unbound drug. Although the sample size
was small, the pharmacologic half-life of 123I-IAZA was
9.8 ± 4.1 h. It is possible that a marker with a shorter phar-
macologic half-life would allow a more rapid recognition of
an increased T/N ratio, if differential binding existed.
A hypothetical example is shown in Figure 4. In this
schema, we assume a simple 2-compartment model in which
phases I, II and III indicate the infusion, distribution and
excretion of the marker, respectively. Consider two
hypothetical markers 'A' and 'B', with pharmacological half-
lives of 5 and 8 h respectively, but otherwise equivalent dis-
tribution characteristics and rates of hypoxic binding.
Although marker binding to hypoxic regions may com-
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Figdre 3 IAZA pharmacokinetics. Blood activity-time curves are
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mence even during the infusion phase, it is clear that the
maximal rates of drug binding will occur in phases II and the
early part of phase III, when the concentration of unbound
marker in tissue is maximal. Although the marker concentra-
tion will change with time, it is at times of maximum marker
concentration in which most hypoxic cell labelling will occur;
we further assume that the covalently bound sensitiser
adducts are stable in tissues (Chapman et al., 1983). Hypoxic
markers will also bind to normal tissue or areas of oxic
tumour, albeit at a rate at least 10-fold less than in the
hypoxic tumour (Chapman et al., 1989b, Cobb et al., 1990).
This differential binding would result in a maximum tumour
to normal tissue ratio of approximately ten. The development
of a differential between marker signal in hypoxic and
aerobic tissue will occur after the concentration of unbound
drug falls below that of the bound drug in hypoxic regions.
From Figure 4 (inset), it is clear that the T/N ratio will
increase with time, and should approach a limit which is
governed by the differential rate of binding in hypoxic vs
aerobic tissue, once unbound marker has been cleared. In
this schema, it is clear that the optimal window for imaging
hypoxia will occur after at least three drug half-lives. As
noted in Figure 4 (inset), the hypoxic marker with a shorter
pharmacologic half-life (A) displays a more rapid increase in
T/N ratio with time after infusion compared to marker B.
Finally, it must be remembered that the radioactive half-life
of the isotope, in contrast to the pharmacokinetic half-life of
the marker molecule, must be long enough to allow for
successful imaging at the optimum time (i.e. > three phar-
macokinetic half-lives). This is one potential limitation of
18F-fluoromisonidazole and positron emission tomographic
imaging (Koh et al., 1989; Rasey et al., 1989), for which the
isotopic half-life is 109.7 min.
With the doses of '23I-IAZA used, the optimum time for
imaging seems to be 24 h post infusion. At this time, we have
observed focal accumulation of activity in three of ten lesions
studied; in these patients, tumour to normal tissue ratios
were seen to rise over the 24 h period subsequent to the
123I-IAZA infusion. We postulate that this represents
metabolic binding of the tracer in these tumours due to
sensitiser adduct formation in hypoxic regions. However, the
in vivo stability of the carbon/iodine linkage is of some
concern, since, partial in vivo deiodination was observed from
scintigraphic data. We plan to perform sequential HPLC
analyses from plasma specimens to determine the extent and
time course of this phenomenon.
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Figure 4 Schema for hypoxic cell labelling in human tumours. A
hypothetical model for the in vivo fate of two hypoxic cell
markers 'A' and 'B' is shown. It is proposed that such markers
are distributed into well- and poorly-perfused tissues after injec-
tion, and then unbound marker is thereafter eliminated. With
time a differential retention is observed between the hypoxic
fraction of the tumour and background normal tissue; T/N ratio
should increase if significant hypoxia is present (inset). Legend: I,
II, III: phases of infusion, distribution and excretion respectively.
tl, t2: times to end of infusion and distribution phases, respec-
tively (not to scale). M: period of maximum rate of IAZA
binding; 0: concentration of IAZA bound to hypoxic tumour;
+: concentration of IAZA bound to normal tissue or aerobic
tumour; ----: concentration of unbound IAZA in any tissue.
(Inset). Relationship of tumour/normal tissue ratio to time after
infusion. x: T/N tissue ratio for hypoxic marker 'A' with
pharmacologic T1/2 = 5 h. 0: T/N tissue ratio for hypoxic
marker 'B' with pharmacologic T1/2 = 8 h.
It is recognised that the patient population of this pilot
study is heterogeneous in terms of histologic type and prior
treatment. No correlation was seen between '231I-IAZA dose
and uptake. Seven of the ten patients imaged were under-
going, or had just begun to receive cytotoxic therapy
(radiotherapy in five cases and chemotherapy in two, Table
I). It is unknown to what extent reoxygenation may have
occurred in these patients after one or more fractions of
radiotherapy. Nonetheless, two out of seven treated tumours
showed '23I-IAZA avidity, while such avidity was seen in one
out of three untreated tumours. We plan to investigate the
change in '231I-IAZA avidity with time in selected patients, as
this may lead to valuable inferences regarding reoxygenation.
Of the factors affecting the tumour microenvironment, it is
likely that blood flow exerts a fundamental influence on
oxygen and metabolic substrate supply (Vaupel et al., 1989).
An experimental non-invasive marker for tumour perfusion is
9'9Tc-hexamethylpropyleneamine oxime (99'Tc-HMPAO)
(Hammersley et al., 1987; Rowell et al., 1989). We plan to
investigate further the relationship between tumour '231-IAZA
avidity and tumour perfusion by sequential imaging with the
hypoxic marker and 99'Tc-HMPAO.
This pilot study will continue to accrue patients prior to
radiotherapy. Patients will be followed and end points of
tumour response and local control ascertained. There is no
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'gold standard' technique for predicting tissue oxygenation,
thus independent confirmation of these results is problematic.
It may be possible to assess the oxygenation status ofaccessi-
ble lesions using needle oximetry as a comparison. Further
clinical experience is required in order to determine whether
the tumour uptake of IAZA or related compounds will
independently correlate with radioresponsiveness and local
control.
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